课题基金 / 基金详情

Novel role of very long chain fatty acids in the brain

Novel role of very long chain fatty acids in the brain
超长链脂肪酸在大脑中的新作用
批准号:
8807392
负责人:
ROBERT E ANDERSON
金额:
$21.98万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-30 至 2016-08-31

项目摘要

项目成果

ROBERT E ANDERSON的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):我们的实验室是第一个发现超长链脂肪酸延伸-4 (ELOVL4)是一种延长酶,负责超长链(VLC; eC26)脂肪酸的生物合成,这些脂肪酸被发现是更复杂的脂质分子(如鞘脂和磷脂酰胆碱)的成分。ELOVL4合成视网膜和睾丸中的VLC多不饱和脂肪酸(VLC- pufa),以及皮肤和大脑中的VLC饱和脂肪酸(VLC- fa)。突变体ELOVL4缺乏合成这些脂肪酸的能力,其杂合遗传导致常染色体显性Stargardt's macular dystrophy (STGD3)的幼年性黄斑变性。具有STGD3突变(ELOVL4突变体/突变体)纯合遗传的人,因此不会产生VLC- PUFA/VLC- fa,会发生鱼鳞病、癫痫、智力残疾和痉挛性四肢瘫痪,并在生命的最初几年内死亡。这建立了ELOVL4突变与神经退行性疾病之间的因果关系;除此之外,我们对VLC-FA在大脑中的作用和重要性一无所知。本课题组发现VLC-FA存在于大鼠脑鞘脂中。我们已经成功地建立了一个动物模型,再现了人类的状况。这种独特的动物模型将使我们能够研究ELOVL4和VLC-FA在神经细胞发育、结构和功能中的作用,这是一个新的和未开发的研究领域。我们的中心假设是,VLC-FA在中枢神经系统中尚未描述的活动的发展/维持中发挥重要作用,ELOVL4的突变和/或VLC-FA的缺失导致神经功能受损,表现为过度兴奋和癫痫发作。这一新颖的假设和本文提出的研究将使我们在理解神经发育和ELOVL4及其VLC-FA产物在大脑中的生物学作用方面取得新的突破。我们提出以下三个具体目标来检验我们的假设。在这个R21申请中,我们提出了一系列的实验,这些实验将为我们提供第二年提交R01申请所需的基本信息。1. 为了验证中枢神经系统中VLC-FA的缺失足以导致神经发育受损从而导致神经功能障碍和癫痫发作的假设。2. 目的探讨ELOVL4及其产物在中枢神经系统内的表达模式。3. 确定ELOVL4突变和/或VLC-FA缺失介导的神经功能障碍机制。
英文摘要
DESCRIPTION (provided by applicant): Our lab was the first to discover that ELOngation of Very Long chain fatty acids-4 (ELOVL4) is an elongase responsible for biosynthesis of very long chain (VLC; eC26) fatty acids that are found as components of more complex lipid molecules such as sphingolipids and phosphatidylcholine. ELOVL4 synthesizes the VLC polyunsaturated fatty acids (VLC-PUFA) found in retina and testes, and VLC saturated fatty acids (VLC-FA) in skin and brain. Heterozygous inheritance of mutant ELOVL4, which lacks the ability to synthesize these fatty acids, causes juvenile macular degeneration in autosomal dominant Stargardt's macular dystrophy (STGD3). Humans with homozygous inheritance of the STGD3 mutation (ELOVL4 mutant/mutant), and thus make no VLC- PUFA/VLC-FA, develop ichthyosis, seizures, intellectual disability, and spastic quadriplegia, and die within the first few years of ife. This establishes a causal link between the mutation in ELOVL4 to a neurodegenerative disease; other than that, nothing is known about the role and importance of VLC-FA in the brain. Our group showed that VLC-FA are in sphingolipids in the rat brain. We have successfully generated an animal model that recapitulates the human condition. This unique animal model will enable us to study the role of ELOVL4 and VLC-FA in neural cell development, structure and function, which is a novel and unexplored area of research. Our central hypothesis is that VLC-FA play an important role in the development/maintenance of as yet undescribed activities in the CNS and that mutations in ELOVL4 and/or loss of VLC-FA lead to impaired neural function, evident by hyper-excitability and seizures. This novel hypothesis and the studies proposed herein to test it will allow us to break new ground in understanding neural development and the biological role of ELOVL4 and its VLC-FA products in the brain. We propose the following three specific aims to test our hypothesis. In this R21 application, we propose a series of experiments that will provide us with the basic information we will need to submit an R01 application in the second year. 1. To test the hypothesis that a loss of VLC-FA within the CNS is sufficient to cause impaired neural development leading to neural dysfunction and seizures. 2. To characterize the expression pattern of ELOVL4 and its products within the CNS. 3. To determine the mechanism of neural dysfunction mediated by mutations in ELOVL4 and/or loss of VLC-FA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Retinal Degeneration Conference
Retinal Degeneration Conference
Retinal Degeneration Conference
Retinal Degeneration Conference
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: